Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Sexually Transmitted Diseases

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 50 articles:
HTML format
Text format



Single Articles


    March 2017
  1. PORCEDDU SV, Milne R, Brown E, Bernard A, et al
    Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.
    Oral Oncol. 2017;66:81-86.
    PubMed     Text format     Abstract available


    February 2017
  2. GELTZEILER M, Clayburgh D, Gleysteen J, Gross ND, et al
    Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically.
    Oral Oncol. 2017;65:89-93.
    PubMed     Text format     Abstract available


    January 2017
  3. MARTEL M, Alemany L, Taberna M, Mena M, et al
    The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma.
    Oral Oncol. 2017;64:37-43.
    PubMed     Text format     Abstract available


    December 2016
  4. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Corrigendum to 'Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents' [Oral Oncol. 62 (2016) 20-27].
    Oral Oncol. 2016 Dec 30. pii: S1368-8375(16)30270.
    PubMed     Text format    


  5. JEANNON JP, Tanaka A, Thavaraj S, Guerrero-Urbano T, et al
    ATR gene mutations in HPV negative oropharyngeal cancer.
    Oral Oncol. 2016 Dec 22. pii: S1368-8375(16)30244.
    PubMed     Text format    


  6. CHERA B, Wang K, Monroe A, Galloway T, et al
    Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?
    Oral Oncol. 2016 Dec 16. pii: S1368-8375(16)30234.
    PubMed     Text format    


  7. INGLEHART RC, Taberna M, Pickard RK, Hoff M, et al
    HPV knowledge gaps and information seeking by oral cancer patients.
    Oral Oncol. 2016;63:23-29.
    PubMed     Text format     Abstract available


    November 2016
  8. D'SOUZA G, Anantharaman D, Gheit T, Abedi-Ardekani B, et al
    Effect of HPV on head and neck cancer patient survival, by region and tumor site: A comparison of 1362 cases across three continents.
    Oral Oncol. 2016;62:20-27.
    PubMed     Text format     Abstract available


  9. HAUGHEY BH, Sinha P, Kallogjeri D, Goldberg RL, et al
    Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx.
    Oral Oncol. 2016;62:11-19.
    PubMed     Text format     Abstract available


  10. MIRGHANI H, Casiraghi O, Guerlain J, Amen F, et al
    Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
    Oral Oncol. 2016;62:101-108.
    PubMed     Text format     Abstract available


    September 2016
  11. D'SOUZA G, Zhang Y, Merritt S, Gold D, et al
    Patient experience and anxiety during and after treatment for an HPV-related oropharyngeal cancer.
    Oral Oncol. 2016;60:90-5.
    PubMed     Text format     Abstract available


  12. CHATURVEDI AK, D'Souza G, Gillison ML, Katki HA, et al
    Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population.
    Oral Oncol. 2016;60:61-7.
    PubMed     Text format     Abstract available


    August 2016
  13. NOHATA N, Abba MC, Gutkind JS
    Unraveling the oral cancer lncRNAome: Identification of novel lncRNAs associated with malignant progression and HPV infection.
    Oral Oncol. 2016;59:58-66.
    PubMed     Text format     Abstract available


    July 2016
  14. SABER CN, Gronhoj Larsen C, Dalianis T, von Buchwald C, et al
    Immune cells and prognosis in HPV-associated oropharyngeal squamous cell carcinomas: Review of the literature.
    Oral Oncol. 2016;58:8-13.
    PubMed     Text format     Abstract available


    May 2016
  15. FENG Y, Li Y, Zhang Y, Zheng H, et al
    Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2016;56:78-83.
    PubMed     Text format     Abstract available


  16. ZAFEREO ME, Xu L, Dahlstrom KR, Viamonte CA, et al
    Squamous cell carcinoma of the oral cavity often overexpresses p16 but is rarely driven by human papillomavirus.
    Oral Oncol. 2016;56:47-53.
    PubMed     Text format     Abstract available


  17. LAROCCA CJ, Han J, Salzwedel AO, Davydova J, et al
    Oncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2016;56:25-31.
    PubMed     Text format     Abstract available


  18. AMINI A, Jasem J, Jones BL, Robin TP, et al
    Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.
    Oral Oncol. 2016;56:1-7.
    PubMed     Text format     Abstract available


    April 2016
  19. ROOPER LM, Gandhi M, Bishop JA, Westra WH, et al
    RNA in-situ hybridization is a practical and effective method for determining HPV status of oropharyngeal squamous cell carcinoma including discordant cases that are p16 positive by immunohistochemistry but HPV negative by DNA in-situ hybridization.
    Oral Oncol. 2016;55:11-6.
    PubMed     Text format     Abstract available


  20. KANG H, Kwon M, Park JJ, Kim JP, et al
    Clinical implications of human papilloma virus and other biologic markers in nasopharyngeal cancer.
    Oral Oncol. 2016;55:e7-e10.
    PubMed     Text format    


    March 2016
  21. SEDGHIZADEH PP, Billington WD, Paxton D, Ebeed R, et al
    Is p16-positive oropharyngeal squamous cell carcinoma associated with favorable prognosis? A systematic review and meta-analysis.
    Oral Oncol. 2016;54:15-27.
    PubMed     Text format     Abstract available


  22. SHER DJ, Schwartz DL, Nedzi L, Khan S, et al
    Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis.
    Oral Oncol. 2016;54:58-67.
    PubMed     Text format     Abstract available


  23. OZRETIC L, Wagner S, Huebbers CU, Gattenlohner S, et al
    FGFR1 amplification and co-overexpression of c-MYC in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;54:e7-9.
    PubMed     Text format    


    February 2016
  24. FIRMINO N, Martinez VD, Rowbotham DA, Enfield KS, et al
    HPV status is associated with altered PIWI-interacting RNA expression pattern in head and neck cancer.
    Oral Oncol. 2016 Feb 4. pii: S1368-8375(16)00015.
    PubMed     Text format     Abstract available


    January 2016
  25. MAZUREK AM, Rutkowski T, Fiszer-Kierzkowska A, Malusecka E, et al
    Assessment of the total cfDNA and HPV16/18 detection in plasma samples of head and neck squamous cell carcinoma patients.
    Oral Oncol. 2016 Jan 11. pii: S1368-8375(15)00428.
    PubMed     Text format     Abstract available


  26. SAMUELS SE, Tao Y, Lyden T, Haxer M, et al
    Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
    Oral Oncol. 2016 Jan 5. pii: S1368-8375(15)00416.
    PubMed     Text format     Abstract available


  27. GUO T, Rettig E, Fakhry C
    Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2016;52:97-103.
    PubMed     Text format     Abstract available


    December 2015
  28. WOODY NM, Koyfman SA, Xia P, Yu N, et al
    Regional control is preserved after dose de-escalated radiotherapy to involved lymph nodes in HPV positive oropharyngeal cancer.
    Oral Oncol. 2015 Dec 17. pii: S1368-8375(15)00370.
    PubMed     Text format     Abstract available


  29. CHUNG CH, Rudek MA, Kang H, Marur S, et al
    A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
    Oral Oncol. 2015 Dec 15. pii: S1368-8375(15)00398.
    PubMed     Text format     Abstract available


    October 2015
  30. TAKES RP, Wierzbicka M, D'Souza G, Jackowska J, et al
    HPV vaccination to prevent oropharyngeal carcinoma: What can be learned from anogenital vaccination programs?
    Oral Oncol. 2015 Oct 28. pii: S1368-8375(15)00355.
    PubMed     Text format     Abstract available


  31. LEE YS, Park JY, Cho KJ, Kim SB, et al
    Composition of inflammatory cells regulating the response to concurrent chemoradiation therapy for HPV (+) tonsil cancer.
    Oral Oncol. 2015 Oct 13. pii: S1368-8375(15)00331.
    PubMed     Text format     Abstract available


    September 2015
  32. RAMQVIST T, Mints M, Tertipis N, Nasman A, et al
    Studies on human papillomavirus (HPV) 16 E2, E5 and E7 mRNA in HPV-positive tonsillar and base of tongue cancer in relation to clinical outcome and immunological parameters.
    Oral Oncol. 2015 Sep 25. pii: S1368-8375(15)00327.
    PubMed     Text format     Abstract available


    July 2015
  33. VAN MONSJOU HS, Schaapveld M, van den Brekel MW, Balm AJ, et al
    The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change?
    Oral Oncol. 2015 Jul 24. pii: S1368-8375(15)00258.
    PubMed     Text format     Abstract available


  34. LIU SZ, Zandberg DP, Schumaker LM, Papadimitriou JC, et al
    Correlation of p16 expression and HPV type with survival in oropharyngeal squamous cell cancer.
    Oral Oncol. 2015 Jul 13. pii: S1368-8375(15)00263.
    PubMed     Text format     Abstract available


    June 2015
  35. DAHLSTROM KR, Bell D, Hanby D, Li G, et al
    Socioeconomic characteristics of patients with oropharyngeal carcinoma according to tumor HPV status, patient smoking status, and sexual behavior.
    Oral Oncol. 2015 Jun 25. pii: S1368-8375(15)00239.
    PubMed     Text format     Abstract available


  36. DALIANIS T, Grun N, Koch J, Vlastos A, et al
    Human papillomavirus DNA and p16 expression in hypopharyngeal cancer and in relation to clinical outcome, in Stockholm, Sweden.
    Oral Oncol. 2015 Jun 25. pii: S1368-8375(15)00236.
    PubMed     Text format     Abstract available


  37. ANDERSON KS, Gerber JE, D'Souza G, Pai SI, et al
    Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.
    Oral Oncol. 2015 Jun 18. pii: S1368-8375(15)00229.
    PubMed     Text format     Abstract available


  38. CHAWLA JP, Iyer N, Soodan KS, Sharma A, et al
    Role of miRNA in cancer diagnosis, prognosis, therapy and regulation of its expression by Epstein-Barr virus and human papillomaviruses: With special reference to oral cancer.
    Oral Oncol. 2015 Jun 17. pii: S1368-8375(15)00230.
    PubMed     Text format     Abstract available


  39. YOUNG D, Xiao CC, Murphy B, Moore M, et al
    Increase in head and neck cancer in younger patients due to human papillomavirus (HPV).
    Oral Oncol. 2015 Jun 8. pii: S1368-8375(15)00182.
    PubMed     Text format     Abstract available


    May 2015
  40. ANDERSON KS, Dahlstrom KR, Cheng JN, Alam R, et al
    HPV16 antibodies as risk factors for oropharyngeal cancer and their association with tumor HPV and smoking status.
    Oral Oncol. 2015 May 6. pii: S1368-8375(15)00186.
    PubMed     Text format     Abstract available


  41. SINHA P, Kallogjeri D, Gay H, Thorstad WL, et al
    High metastatic node number, not extracapsular spread or N-classification is a node-related prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer.
    Oral Oncol. 2015;51:514-20.
    PubMed     Text format     Abstract available


    March 2015
  42. MIRGHANI H, Amen F, Moreau F, Lacau St Guily J, et al
    Do high-risk human papillomaviruses cause oral cavity squamous cell carcinoma?
    Oral Oncol. 2015;51:229-36.
    PubMed     Text format     Abstract available


    February 2015
  43. OSAZUWA-PETERS N, Wang DD, Namin A, Vivek J, et al
    Sexual behavior, HPV knowledge, and association with head and neck cancer among a high-risk group.
    Oral Oncol. 2015 Feb 12. pii: S1368-8375(15)00023.
    PubMed     Text format     Abstract available


  44. FOTOPOULOS G, Pavlidis N
    The role of human papilloma virus and p16 in occult primary of the head and neck: a comprehensive review of the literature.
    Oral Oncol. 2015;51:119-23.
    PubMed     Text format     Abstract available


  45. TANG C, Fuller CD, Garden AS, Awan MJ, et al
    Characteristics and kinetics of cervical lymph node regression after radiation therapy for human papillomavirus-associated oropharyngeal carcinoma: quantitative image analysis of post-radiotherapy response.
    Oral Oncol. 2015;51:195-201.
    PubMed     Text format     Abstract available


    January 2015
  46. LOUIE KS, Mehanna H, Sasieni P
    Trends in head and neck cancers in England from 1995 to 2011 and projections up to 2025.
    Oral Oncol. 2015 Jan 22. pii: S1368-8375(15)00003.
    PubMed     Text format     Abstract available


  47. HADDAD RI, Chan AT, Vermorken JB
    Barriers to clinical trial recruitment in head and neck cancer.
    Oral Oncol. 2015 Jan 13. pii: S1368-8375(14)00379.
    PubMed     Text format     Abstract available


    December 2014
  48. JENKINS WD, LeVault K, Sutcliffe S
    Chlamydia trachomatis infection: Possible cofactor for oropharyngeal cancer development?
    Oral Oncol. 2014 Dec 11. pii: S1368-8375(14)00354.
    PubMed     Text format    


  49. ROE JW, Drinnan MJ, Carding PN, Harrington KJ, et al
    Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia?
    Oral Oncol. 2014;50:1182-7.
    PubMed     Text format     Abstract available


    October 2014
  50. MYDLARZ WK, Chan JY, Richmon JD
    The role of surgery for HPV-associated head and neck cancer.
    Oral Oncol. 2014 Oct 30. pii: S1368-8375(14)00300.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Sexually Transmitted Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: